About the deal
Ceva Santé Animale is a French multinational veterinary pharmaceutical company created in 1999. Ceva specializes in the innovation, development, production and marketing of pharmaceutical products and vaccines for livestock (ruminants, swine, poultry) and companion animals. Ceva is present in 46 countries and employs over 6000 people worldwide. Ceva has achieved sustained and profitable growth over the last 20 years, reaching over €1.2 billion in revenues and will now join the global top 5 animal health companies.
Sofiproteol is an investment company with almost €800m assets under management that supports companies in the agro & food industries through financing solutions. As a core long-standing shareholder Sofiprotéol re-invests into Ceva Santé Animale to further participate and contribute to Ceva’s future growth, together with the management, Théthys Invest (investment holding of the Bettencourt-Meyers family), PSP Investments, Mitsui & Co, Mérieux Equity Partners, Temasek, EMZ, Sagard, Hopu and Continental Grain.
What we did
Capitalmind has advised Sofiproteol on its equity investment into Ceva Santé Animale, providing critical analysis of the investment, valuation guidance, execution support, and negotiation of the transaction terms & conditions.
This transaction marks our 15th deal for Avril Group and its investment vehicle Sofiproteol.